Press Releases
Excerpt from the Press Release: PLEASANTON, Calif., July 26, 2023 /PRNewswire/ — Noctrix Health, Inc. announced a double feature in the renowned peer-reviewed journal, Sleep, showcasing the outcomes of two major clinical trials that assessed TOMAC therapy for the treatment of RLS. The two papers feature the results from the RESTFUL study (NCT04874155), a multi-center,…
Read MoreParticipant 1 Achieved Clinically Meaningful Reduction in Plasma Phe of Up to 99% Change from Baseline and Below the U.S. PKU Treatment Guideline Threshold (<360 μmol/L)*; At 31 Weeks Post-Dose, Phe Level 319 μmol/L With a 59% Reduction from Baseline, Even After Dietary Protein Supplementation Participant 2 Plasma Phe Level Reduction of 49% Change from…
Read MoreExcerpt from the Press Release: WATERTOWN, Mass., July 27, 2023 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that the first patient has been enrolled in the National Institutes of Health-sponsored Phase 1/2…
Read More55% objective response rate; 23% complete response rate in locally advanced cSCC 50% objective response rate; 13% complete response rate in metastatic cSCC Cosibelimab continues to demonstrate a favorable safety profile Biologics License Application currently under review by U.S. FDA; PDUFA goal date of January 3, 2024 Excerpt from the Press Release: WALTHAM, Mass., July…
Read MoreExcerpt from the Press Release: SAN DIEGO, July 28, 2023 (GLOBE NEWSWIRE) — Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the Company has committed to fund an unrestricted research grant to the Leiden University Medical Center (LUMC) Anesthesia and Pain Research Unit. The funding will support the work of Albert Dahan,…
Read MoreExcerpt from the Press Release: HANGZHOU, China and SAN FRANCISCO, July 11, 2023 /PRNewswire/ — Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focusing on discovering and developing innovative therapies to treat metabolic disease, today announced the publication of discovery, preclinical characterization, and Phase 1 clinical trial results of its GLP-1 analog ecnoglutide (XW003) in…
Read MoreExcerpt from the Press Release: BOSTON, July 12, 2023 /PRNewswire/ — Velico Medical has begun a Phase I safety study for their FrontlineODP (OnDemandPlasma) Spray Dried Plasma product in a multi-center, dose escalation clinical trial. This first in-human clinical trial using Velico’s spray drying system is taking place at Hoxworth Blood Center, Cincinnati, Ohio; Versiti Blood Center of…
Read More3Daughters aims to uniquely address and fill major gaps in Women’s Health Assembles experienced Women’s Health team and World Class SAB to advance development of novel long-acting reversible contraception technology Excerpt from the Press Release: MANSFIELD, Mass., July 13, 2023 (GLOBE NEWSWIRE) — 3Daughters, an emerging clinical development company fueling evolutionary healthcare for women, announces…
Read MoreResults Published in European Journal of Human Genetics Demonstrate Unprecedented Insights to Accelerate Potential Treatment Options Excerpt from the Press Release: CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 12, 2023 (GLOBE NEWSWIRE) — CENTOGENE N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced…
Read More-Largest randomized trial of DynamX Bioadaptor to date with 2,400 patients enrolled, covering real-world population- Excerpt from the Press Release: MILPITAS, Calif.–(BUSINESS WIRE)–Elixir Medical, a developer of breakthrough cardiovascular technologies, today announced enrollment completion in INFINITY-SWEDEHEART, a prospective, multicenter, single-blind, randomized clinical trial of the DynamX® Coronary Bioadaptor System, the first metallic coronary artery implant…
Read More